Savings to the Colombian health system with the implementation of externally funded oncology clinical trials
Abstract
Introduction. Spending on drugs to treat cancer will increase by 9-12% annually until 2025. For health systems in high and middle-income countries –such as Colombia– and with an increasing trend of new cancer cases, clinical research can contribute to the efficient use of the system resources available without undermining the timeliness and quality of healthcare.
Objective. To calculate the savings generated to the Colombian health system by the implementation of externally funded clinical trials for cancer.
Materials and methods. We conducted an observational, longitudinal, descriptive, and retrospective study analyzing participant’s medical records of clinical trials between 2016 and 2022 at the Clínica IMAT Oncomédica Auna, Colombia.
Results. The total savings to the health system for external financing of oncology drugs was USD $1,526,320, and the monthly weighted average savings per patient was USD $3,257. The participation of breast cancer patients in randomized controlled clinical trials (n = 138) accounted for 24% (USD $369,363) of the total savings. Participants with clinical stage IV and III accounted for 41.7% (USD $636,475) and 31.06% (USD $473,159), respectively, of the total savings to the general social security health system in Colombia from external financing of oncological drugs.
Conclusion. The participation of cancer patients in clinical trials mitigated costs to the Colombian health system, especially in women with breast cancer and in those patients with clinical stage IV of the disease.
Downloads
References
1. World Health Organization. Global expenditure on health: Public spending on the rise? Geneva: WHO; 2021. Fecha de consulta: 17 de abril de 2023. Disponible en: https://www.who.int/publications/i/item/9789240041219
2. Barón-Leguizamón G. Composición y evolución del gasto en salud de Colombia y su financiamiento en el periodo 2013-2018. Rev Salud Pública. 2022;24:1-9. https://doi.org/10.15446/rsap.v24n1.103052
3. IQVIA Institute. Global medicine spending and usage trends: Outlook to 2025. Parsippany, NJ: IQVIA Institute; 2021. Fecha de consulta: 25 de abril de 2023. Disponible en: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicine-spending-and-usagetrends-outlook-to-2025
4. Dirección de Epidemiología y Demografía. Análisis de situación de salud, Colombia 2022. Bogotá; 2023. Fecha de consulta: 25 de abril de 2023. Disponible en: https://www.minsalud.gov.co/salud/publica/epidemiologia/Paginas/analisis-de-situacion-de-salud-.aspx
5. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204-22. https://doi.org/10.1016/S0140-6736(20)30925-9
6. Sánchez G. Investigación clínica en seres humanos en Colombia. ¿Estamos en crisis? Acta Médica Colombiana. 2017;42:207-9. https://doi.org/10.36104/amc.2017.1411
7. Asociación Colombiana de Centros de Investigación Clínica. Boletín 6. 2022. Fecha de consulta: 18 de abril de 2023. Disponible en: https://aciccolombia.org/boletines-acic/
8. ClinicalTrials.gov. Studies on map - ClinicalTrials.gov. Fecha de consulta: 18 de abril de 2023. Disponible en: https://clinicaltrials.gov/ct2/search/map/click?map.x=444&map.y=505&mapw=1325
9. Consejo de Organizaciones Internacionales de las Ciencias Médicas (CIOMS), Organización Mundial de la Salud (OMS), Organización Panamericana de la Salud (OPS). Pautas éticas internacionales para la investigación relacionada con la salud con seres humanos. Cuarta edición. Ginebra: Consejo de Organizaciones Internacionales de las Ciencias Médicas (CIOMS); 2016. Fecha de consulta: 18 de abril de 2023. Disponible en: https://cioms.ch/wp-content/uploads/2018/01/CIOMS-EthicalGuideline_SP_WEB.pdf
10. White F. Capacity-building for health research in developing countries: A manager’s approach. Rev Panam Salud Pública. 2002;12:165-72. https://doi.org/10.1590/s1020-49892002000900004
11. Liberman F, Elgart J, Strusberg I. Economic benefit of sponsored controlled clinical trials: The avoidable cost in drugs for the treatment of rheumatoid arthritis. Value Health Reg Issues. 2019;20:7-11. https://doi.org/10.1016/j.vhri.2018.10.007
12. Ripari NV, Elorza ME, Moscoso NS. Custos de doenças: classificação e perspectivas de análise. Rev Cienc Salud. 2017;15:49-58. https://doi.org/10.12804/revistas.urosario.edu.co/revsalud/a.5376
13. International Agency for Research on Cancer (IARC). Cancer today - IARC Globocan 2022 (version 1.1). 2024. Fecha de consulta: 7 de agosto de 2024. Disponible en: https://gco.iarc.who.int/today/
14. International Agency for Research on Cancer (IARC). Cancer tomorrow - IARC Globocan 2022 (version 1.1). 2024. Fecha de consulta: 7 de agosto de 2024. Disponible en: https://gco.iarc.who.int/today/
15. Fondo Colombiano de Enfermedades de Alto Costo, Cuenta de Alto Costo. Situación del cáncer en la población adulta atendida en el SGSSS de Colombia 2022. Bogotá: Fondo Colombiano de Enfermedades de Alto Costo; 2023. Fecha de consulta: 7 de agosto de 2024. Disponible en: https://cuentadealtocosto.org/publicaciones/situacion-del-cancer-en-lapoblacion-adulta-atendida-en-el-sgsss-de-colombia-2022/
16. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): Breast cancer. Version 4, 2022. Fecha de consulta: 7 de agosto de 2024. Disponible en: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419
17. Ayala de la Peña F, Andrés R, García-Sáenz JA, Manso L, Margelí M, Dalmau E, et al. SEOM clinical guidelines in early stage breast cancer (2018). Clin Transl Oncol. 2019;21:18-30. https://doi.org/10.1007/s12094-018-1973-6
18. Chacón López-Muñiz JI, de la Cruz Merino L, Gavilá Gregori J, Martínez Dueñas E, Oliveira M, Seguí Palmer MA, et al. SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clin Transl Oncol. 2019;21:31-45. https://doi.org/10.1007/s12094-018-02010-w
19. Ministerio de Salud y Protección Social. Guía de práctica clínica para tratamiento integral, seguimiento y rehabilitación del cáncer de mama. 2a edición. Guía No. 19. Bogotá: Ministerio de Salud y Protección Social; 2017. Fecha de consulta: 17 de diciembre de 2022. Disponible en: https://www.cancer.gov.co/recursos_user/masivos/guias_publicadas_917/GPC_Ca_Mama_v.pdf
20. Sun L, Legood R, dos-Santos-Silva I, Gaiha SM, Sadique Z. Global treatment costs of breast cancer by stage: A systematic review. PLoS ONE. 2018;13:e0207993. https://doi.org/10.1371/journal.pone.0207993
21. Polignano MG, Pasculli G, Trisolini P, Di Lorenzo MA, Dalfino G, Giannelli G. Economic impact of industry-sponsored clinical trials in inflammatory bowel diseases: Results from the National Institute of Gastroenterology “Saverio de Bellis”. Front Pharmacol. 2022;13. https://doi.org/10.3389/fphar.2022.1027760
22. Carmona A, Cransac A, Gueneau P, Caillot D, Pernot C. Évaluation des coûts médicamenteux évités grâce aux inclusions des patients atteints d’hémopathie maligne dans les essais cliniques. Pharm Hosp Clin. 2020;55:73-8. https://doi.org/10.1016/j.phclin.2019.10.005
23. Brown JN, Tillman F, Jacob S, Britnell SR. Economic outcomes associated with an investigational drug service within a veterans affairs health care system. Contemp Clin Trials Commun. 2019;14:100354. https://doi.org/10.1016/j.conctc.2019.100354
24. Calvin-Lamas M, Portela-Pereira P, Rabuñal-Álvarez MT, Martínez-Breijo S, Martín-Herranz MI, Gómez-Veiga F. Coste evitado en medicamentos de ensayos clínicos en cáncer de próstata. Actas Urol Esp. 2015;39:553-7. https://doi.org/10.1016/j.acuro.2015.05.002
25. Sánchez-Martínez DA, Salas-Lucía F, Jiang H, Ruiz-Carreño P, Alonso-Romero JL. Drug cost avoidance analysis of cancer clinical trials in Spain: A study on cost contributors and their impact. BMC Health Serv Res. 2022;22:948. https://doi.org/10.1186/s12913-022-08222-9
26. Shen LJ, Chou H, Huang CF, Chou GM, Chan WK, Wu FLL. Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan. Contemp Clin Trials. 2011;32:485-91. https://doi.org/10.1016/j.cct.2011.04.003
27. Gamboa Ó, Buitrago LA, Lozano T, Dieleman S, Gamboa C, Guzmán EL, et al. Costos directos de la atención del cáncer de mama en Colombia. Rev Colomb Cancerol. 2016;20:52-60. https://doi.org/10.1016/j.rccan.2016.02.003
28. The World Bank. World Bank Country and lending groups: Country classification. Fecha de consulta: 29 de junio de 2023. Disponible en: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
29. Cardona-Zorrilla AF, Rojas-Puentes LL, Robles A, Badillo C, Ceballos J, Sanchez N, et al. Budget impact analysis of participating in sponsored clinical trials in cancer within the Colombian healthcare system: A real-world evidence approach. J Clin Oncol. 2024;42(Suppl.16):e23031. https://doi.org/10.1200/JCO.2024.42.16_suppl.e23031
30. Ioannidis JPA. Why most clinical research is not useful. PLOS Med. 2016;13:e1002049. https://doi.org/10.1371/journal.pmed.1002049
31. Department of Health and Social Care. The future of UK clinical research delivery: 2022 to 2025 implementation plan. Fecha de consulta: 29 de junio de 2023. Disponible en:
32. Yu JB, Schrag D, Robin-Yabroff K. Health economics research in cancer treatment: Current challenges and future directions. JNCI Monogr. 2022;2022:51-6. https://doi.org/10.1093/jncimonographs/lgac009
Some similar items:
- Luz Elena Velásquez, Catalina Gómez, Erika Valencia, Laura Salazar, Eudoro Casas, Paragonimosis in the peri-urban zone of Medellín, Antioquia , Biomedica: Vol. 28 No. 3 (2008)
- Oscar F. Herrán, María F. Ardila, Martha P. Rojas, Gustavo A. Hernández, Design of dietary questionnaires to study the relationships between diet and cancer prevalence in Colombia , Biomedica: Vol. 30 No. 1 (2010)
- Juan Carlos Cataño, Eaton-Lambert myasthenic syndrome , Biomedica: Vol. 30 No. 3 (2010)
- Juan Carlos Herrera, Luis Fernando Isaza, José Luis Ramírez, Gonzalo Vásquez, Carlos Mario Muñetón, Detection of chromosome 17 aneuplody and TP53 gene deletion in a broad variety of solid tumors by dual-color fluorescence in situ hybridization (FISH) , Biomedica: Vol. 30 No. 3 (2010)
- Sandra Milena Arias, Lina Marcela Salazar, Eudoro Casas, Alexandra Henao, Luz Elena Velásquez, Paragonimus sp. in crabs and awareness of the educational community to aquatic ecosystems in La Miel and La Clara, Caldas, Antioquia , Biomedica: Vol. 31 No. 2 (2011)
- Yaliana Tafurt-Cardona, Leidy D. Jaramillo-Ruiz, Wilson Muñoz-Ordóñez, Sulma L. Muñoz-Benítez, Carlos H. Sierra-Torres, High frequency of chromosome aberrations observed in lymphocytes in postmenopausal obese women , Biomedica: Vol. 32 No. 3 (2012)
- Jaiberth Cardona-Arias, Luz Peláez-Vanegas, Juan López-Saldarriaga, Marcela Duque-Molina, Oscar Leal-Álvarez, Health related quality of life in adults with HIV/AIDS in Colombia , Biomedica: Vol. 31 No. 4 (2011)
- Ricardo Cendales, Constanza Pardo, Claudia Uribe, Guillermo López, María Clara Yépez, Luis Eduardo Bravo, Data quality at population-based cancer registries in Colombia , Biomedica: Vol. 32 No. 4 (2012)
- Alvaro Javier Idrovo, Historical, social and epidemiological roots of tuberculosis in Bogotá, Colombia. , Biomedica: Vol. 24 No. 4 (2004)
- Sonia Isabel Cuervo, Ricardo Sánchez, Julio César Gómez-Rincón, Cielo Almenares, Juan Pablo Osorio, María José Vargas, Behavior of carbapenemase-producing Klebsiella pneumoniae cases in cancer patients at a third level hospital in Bogotá, D.C. , Biomedica: Vol. 34 (2014): Abril, Suplemento 1, Resistencia bacteriana
Copyright (c) 2025 Biomedica
This work is licensed under a Creative Commons Attribution 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
Funding data
